)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
Akero Therapeutics
Akero Therapeutics (AKRO) investor relations material
Akero Therapeutics has been acquired by Novo Nordisk
Akero Therapeutics EGM 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.EGM 2025 summary2 Dec, 2025
Opening remarks and agenda
Meeting called to order at 11:00 A.M. Eastern Time, with rules of conduct posted on the web portal.
Inspector of Election appointed and oath filed with meeting minutes.
Notice, proxy statement, and affidavit of mailing made available to all stockholders.
Quorum confirmed with majority of outstanding shares present or represented by proxy.
Specific resolutions to be voted on
Adoption of the Agreement and Plan of Merger with Novo Nordisk A/S and NN Invest Sub Incorporated, including a Contingent Value Rights agreement.
Advisory non-binding approval of compensation to named executive officers in connection with the merger.
Overview of voting outcomes
Merger proposal approved by majority of outstanding shares.
Compensation proposal also approved by majority of outstanding shares.
Adjournment proposal not presented as merger was approved.
Detail CVR agreement terms
Akero's operational independence post-merger
Rationale for executive merger compensation
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Akero Therapeutics
- Efruxifermin delivers fast, significant fibrosis improvement, with key F4 data due in Q1.AKRO
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Efruxifermin delivers unprecedented fibrosis improvement in NASH, advancing through phase III trials.AKROMorgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026
- Efruxifermin delivers strong, sustained fibrosis improvement and is positioned for broad NASH use.AKROH.C. Wainwright 8th Annual NASH Virtual Conference19 Jan 2026
- Anticipated two-year F4 cirrhosis data could reshape the NASH/MASH market landscape.AKROJefferies London Healthcare Conference 202413 Jan 2026
- Efruxifermin advances in NASH/MASH with strong efficacy, key data in 2025, and solid cash reserves.AKRO7th Annual Evercore ISI HealthCONx Healthcare Conference12 Jan 2026
- Efruxifermin shows durable fibrosis reversal and strong safety, with pivotal data expected by 2027.AKRO43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026
- 50 mg EFX achieved significant and durable cirrhosis reversal and MASH resolution at 96 weeks.AKROStudy Result9 Jan 2026
- Merger proposal offers $54/share plus $6 CVR; board and advisors unanimously support approval.AKROProxy Filing2 Dec 2025
- Shareholders will vote on director elections, auditor ratification, and executive pay approval.AKROProxy Filing2 Dec 2025
Akero Therapeutics
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage